Canadian drugs sales level off while R&D budgets fall
This article was originally published in Scrip
Pharmaceutical sales grew just 1.7% in 2011 from Can$12.9 billion to Can$13.1 billion according to Canada's Patented Medicine Prices Review Board (PMPRB), which has the legal mandate of ensuring that medicines prices in Canada are not excessive. Indeed the increase in the total spend on medicines can be attributed to the introduction of new medicines rather than changes in prices.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.